Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID-19 vaccination and cancer immunotherapy: should they stick together?
Patrick Brest, Baharia Mograbi, Paul Hofman, et al.
British Journal of Cancer (2021) Vol. 126, Iss. 1, pp. 1-3
Open Access | Times Cited: 18

Showing 18 citing articles:

Incidence of severe adverse events in cancer patients after treatment with immune-checkpoint inhibitors during the COVID- 19 pandemic
Sakiko Kimura, Hiroo Katsuya, Chiho Nakashima, et al.
BMC Immunology (2025) Vol. 26, Iss. 1
Open Access | Times Cited: 1
COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis
Juan Ignacio Ruiz, María A. López-Olivo, Yimin Geng, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 2, pp. e006246-e006246
Open Access | Times Cited: 19
In materia implementation strategies of physical reservoir computing with memristive nanonetworks
Gianluca Milano, Kevin Montano, Carlo Ricciardi
Journal of Physics D Applied Physics (2023) Vol. 56, Iss. 8, pp. 084005-084005
Open Access | Times Cited: 18
Nano Device Fabrication for In-memory and In-sensor Reservoir Computing
Yinan Lin, Xi Chen, Qianyu Zhang, et al.
International Journal of Extreme Manufacturing (2024) Vol. 7, Iss. 1, pp. 012002-012002
Open Access | Times Cited: 5
Cytokine release syndrome in a patient with non-small cell lung cancer on ipilimumab and nivolumab maintenance therapy after vaccination with the mRNA-1273 vaccine: a case report
Toshiyuki Sumi, Yuta Koshino, Haruhiko Michimata, et al.
Translational Lung Cancer Research (2022) Vol. 11, Iss. 9, pp. 1973-1976
Open Access | Times Cited: 18
Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors
Danielle Gilbert, Junxiao Hu, Theresa Medina, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 9
Immunogenicity and Safety of Vaccines against Coronavirus Disease in Actively Treated Patients with Solid Tumors: A Prospective Cohort Study
Yae Jee Baek, Youn-Jung Lee, So Ra Park, et al.
Cancer Research and Treatment (2023) Vol. 55, Iss. 3, pp. 746-757
Open Access | Times Cited: 5
Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors
Fabrizio Nelli, Diana Giannarelli, Agnese Fabbri, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 10, pp. 3217-3228
Open Access | Times Cited: 4
Changes in Peripheral Immune Cells after the Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine and Disease Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Prospective Analysis of the Vax-on-Third-Profile Study
Fabrizio Nelli, Carlo Signorelli, Agnese Fabbri, et al.
Cancers (2023) Vol. 15, Iss. 14, pp. 3625-3625
Open Access | Times Cited: 3
Psychotropic drugs interaction with the lipid nanoparticle of COVID-19 mRNA therapeutics
Adonis Sfera, Sabine Hazan, Jonathan J. Anton, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 5
An open call for nano-based therapy to address COVID-19 and oncological clinical conditions
Rasmita Dash, Rudra Narayan Sahoo, Gurudutta Pattnaik, et al.
International Journal of Surgery (2023) Vol. 110, Iss. 4, pp. 2430-2432
Open Access | Times Cited: 2
Biological modifications of the immune response to COVID-19 vaccine in patients treated with anti-CD20 agents and immune-checkpoint inhibitors
Francesco Ravera, Martina Dameri, Isabella Lombardo, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Patients with advanced cancer were treated with immune checkpoint inhibitors and injected with COVID-19 vaccine to improve their prognosis without increasing pancreatic related adverse events
Min Li, Lingling Liao, Wei Huang, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access
Programmed Cell Death Protein 1 Axis Inhibition in Viral Infections: Clinical Data and Therapeutic Opportunities
Konstantinos Tsiakos, Niki Gavrielatou, Ioannis Vathiotis, et al.
Vaccines (2022) Vol. 10, Iss. 10, pp. 1673-1673
Open Access | Times Cited: 2
Perception and safety analysis of COVID‐19 vaccination in cancer patients: A multicenter, real‐world study
Kyoungmin Lee, In Hae Park, Sang Cheul Oh, et al.
Cancer Medicine (2022) Vol. 12, Iss. 5, pp. 5558-5568
Open Access | Times Cited: 2
The effect of COVID-19 on cancer immunotherapy and cancer care
John E. Niederhuber
Elsevier eBooks (2023), pp. 289-310.e7
Closed Access
Exploring hematic crasis variations in cancer patients following SARS-CoV-2 vaccination: a real-practice study
Liliana Montella, Carmela Dell’Aversana, Daniela Pacella, et al.
Infectious Agents and Cancer (2023) Vol. 18, Iss. 1
Open Access
Effects of the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine on immune-related adverse events and disease outcomes in cancer patients receiving immune checkpoint inhibitors
Fabrizio Nelli, Diana Giannarelli, Agnese Fabbri, et al.
Research Square (Research Square) (2022)
Open Access
Page 1

Scroll to top